EMBC
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Embecta Corp. is a medical device company focused on providing solutions for people living with diabetes. The company manufactures and sells a portfolio of products including conventional and safety pen needles, insulin syringes, and safety injection devices. These sterile, single-use devices are designed for insulin administration and are compatible with widely available pen injectors. Embecta serves patients, healthcare providers, and institutions globally across North America, South America, Europe, the Middle East, Africa, and Asia-Pacific. The company operates manufacturing sites in Ireland, the United States, and China, and distributes its products through retail, hospital, pharmacy, and other institutional channels. Embecta was formed in 2022 following its separation from Becton, Dickinson and Company (BD), and it acquired Owen Mumford to expand its capabilities. The company holds intellectual property rights to its injection technologies and maintains supply agreements with BD for cannula components.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Medical Devices Homepage embecta.com
Sector Healthcare IR page investors.embecta.com
Tags
diabetes care, insulin administration, pen needles, insulin syringes, safety injection devices, drug delivery, medical devices, Owen Mumford, Nano 2nd Gen Pen Needles, The Injection Lab
Press page —

Metrics

Valuation  
Market cap $ 320.693M
Market cap (USD) $ 320.693M
P/E 3.85
PEG —
P/BV -0.52
P/S 0.31
P/OCF 1.84
P/FCF 1.95
Dividend yield 8.1%
Turnover / mcap —
Returns  
ROE -14.7%
ROI 12.8%
ROIC 22.7%
Profit margin 8.8%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) -24.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 1.08B 1.123B 1.121B 1.13B 0
Net profit 95.4M 78.3M 70.4M 223.6M 0
Free cash flow 182.4M 19.9M 41.2M 388.6M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 14.11 14.1 15.05 28.79 —
Price performance 12m 0 -0.06 -0.48 — —

Filed figures

Figure Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Balance sheet detail
Trade receivables (USD) — — 151M 22.2M 16.7M 193M 146M
↳ YoY growth -85.3% -24.8% +1,055.7% -24.6%
Borrowings, current (USD) — — 0.00 9.5M 9.5M 9.5M 9.5M
Borrowings, non-current (USD) — — 0.00 1.6B 1.59B 1.57B 1.39B
Lease liabilities (USD) — — 4M 42.5M 56.4M 51.5M 49.2M
Cash and deposits (USD) 0.00 0.00 0.00 331M 327M 268M 226M
Intangible assets (USD) — — 18.3M 8.9M 9.1M 8.1M 7M
Right-of-use assets (USD) — — 4M 6.3M 23M 22.6M 20.2M
Net debt (borrowings + leases - cash) (USD) — — 0.00 1.32B 1.33B 1.36B 1.22B
Cash flow detail
Operating cash flow (USD) — 499M 456M 412M 67.7M 35.7M 192M
Purchases of property, plant and equipment (USD) — -41.9M -36.8M -23.6M -26.5M -15.8M -9.3M
Purchases of intangible assets (USD) — 0.00 -2.4M -400,000 0.00 0.00 —
Change in receivables (cash effect) (USD) — -2.4M -31.8M 123M 7M -175M 44.2M
Change in inventories (cash effect) (USD) — 3.5M -18M -23.4M -28.8M -16.5M -6.1M
Change in payables (cash effect) (USD) — -3.8M 30.8M 73.3M 7.9M 60M -68.9M
Dividends paid (cash effect) (USD) — 0.00 0.00 -8.6M -34.4M -34.5M -35M
Interest paid (cash effect) (USD) — — — -38.9M -111M -118M -104M
Income taxes paid (cash effect) (USD) — — — -15.6M -30.4M -29.1M -50.1M
Share-based compensation (USD) — 12.7M 12.8M 18.7M 21.5M 26.3M 31.6M
Operating cash flow before change in receivables (USD) — 501M 488M 290M 60.7M 210M 148M
Free cash flow (OCF - PPE - intangibles) (USD) — 457M 417M 388M 41.2M 19.9M 182M
Income detail
Research and development expense (USD) — 61.4M 63.3M 66.9M 85.2M 78.8M 37.3M
↳ 5y CAGR -9.5%
Total comprehensive income (USD) — 444M 406M 159M 86.2M 94.6M 101M
Comprehensive income to owners (USD) — 444M 406M 159M 86.2M 94.6M 101M
Reported Dec 22, 2022 Dec 22, 2022 Dec 22, 2022 Dec 22, 2022 Nov 29, 2023 Dec 11, 2024 Nov 25, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

embecta to Participate in Investor Events Bull 0 Bear 0 Routine

August 31, 2026

PDF Version

PARSIPPANY, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

Wells Fargo 2026 Healthcare Conference Management will host one-on-one investor meetings on Wednesday, September 9, 2026, at the Encore Boston Harbor Hotel in Everett, Boston, MA.

J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 Management will host a fireside chat on Thursday, September 10, 2026, at 8:00 a.m. CT, as well as one-on-one investor meetings, at the Joseph Hotel, Nashville.

About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,500 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

| Contacts: |

| | |

| Media | Investors |

| Christian Glazar | Patricia Gonzalez |

| Sr. Director, Corporate Communications | VP, Corporate FP&A and Investor Relations |

| 908-821-6922 | 862-341-2809 |

| Contact Media Relations | Contact IR |

Stay Informed with Email Alerts

Sign Up

Close

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.

Accept

embecta Announces Quarterly Cash Dividend Bull 0 Bear 0 Capital return

August 7, 2026

PDF Version

PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2026 to stockholders of record at the close of business on August 27, 2026.

About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

August 7, 2026

PDF Version 474.4 KB

PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.

Visit the company’s Investor Relations website at http://investors.embecta.com to view the detailed third quarter fiscal 2026 earnings press release and investor presentation.

The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, Aug 7, 2026, which is accessible here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 7, 2026, via the embecta investor relations website and archived on the website for one year.

About embecta

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Prompts

Embecta Corp. (ticker EMBC), listed in United States.

Company History

Date Change Detail
Aug 12, 2021 Renamed Berra Newco, Inc. → EMBECTA CORP.

ETFs Holding Embecta Corp.

ETF Weight in ETF Shares Market value As of
LITL 0.53% 4,925 $ 30.289K Nov 17, 2026
SQLV 0.49% 43,313 $ 141.2K Jun 30, 2026
VFVA 0.15% 278,691 $ 1.432M Aug 31, 2026
IVSS 0.10% 8,302 $ 27.065K Jun 30, 2026
AFSM 0.02% 4,640 $ 29K Nov 16, 2026
PSC 0.02% 111,307 $ 362.861K Jun 30, 2026
RESM 0.01% 94 $ 306.44 Jun 30, 2026
PINK 0.01% 2,794 $ 17.183K Nov 17, 2026
FESM 0.00% 55,015 $ 179.349K Jun 30, 2026
DFAS 0.00% 44,500 $ 286.135K Nov 12, 2026
ESSC 0.00% 73 $ 265.72 Jul 31, 2026
DCOR 0.00% 32,205 $ 207.078K Nov 12, 2026
DFUS 0.00% 12,065 $ 77.578K Nov 12, 2026
DFAC 0.00% 43,847 $ 281.936K Nov 12, 2026
ACVF 0.00% 130 $ 473.20 Jul 31, 2026